Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets

Chemical and Pharmaceutical Bulletin

Volumn 54, Issue 4, 2006, Pages 409-414

  Makino, Chisato ^a   Ninomiya, Nobutaka ^a   Sakai, Hidetoshi ^a   Orita, Haruo ^a   Okano, Akira ^a   Yabuki, Akira ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Controlled release formulation; Fast acting blood glucose regulator; Fasting blood glucose level (FBG); Nateglinide; Post prandial blood glucose level (PBG)

Indexed keywords

GLUCOSE; INSULIN; NATEGLINIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED RELEASE FORMULATION; CORRELATION ANALYSIS; DIABETES MELLITUS; DOG; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SOLUBILITY; ENTERIC COATED TABLET; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; PH; POSTPRANDIAL STATE;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CYCLOHEXANES; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS; DOGS; FASTING; HYDROGEN-ION CONCENTRATION; HYPOGLYCEMIC AGENTS; PHENYLALANINE; SOLUBILITY; TABLETS, ENTERIC-COATED;

EID: 33645545088     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.54.409     Document Type: Article

References (18)

1. Kondo N., Jpn. J. Clin. Med., 55 (Suppl.), 159-163 (1997).
2. Ikenoue T., Okazaki K., Fujitani S., Tsuchiya Y., Akiyoshi M., Maki T., Kondo N., Biol. Pharm. Bull., 20, 354-359 (1997).
3. Fujitani S., Yada T., Endocrinology, 134, 1395-1400 (1994).
4. Shinkai H., Nishikawa M., Sato Y., Toi K., Kumashiro I., Seto Y., Fukuma M., Dan K., Toyoshima S., J. Med. Chem., 32, 1436-1441 (1989).
5. Akiyoshi M., Okazaki K., Tsuchiya Y., Ikenoue T., Fujitani S., Kondo N., Maki T., Kakei M., Clinical Report, 31, 1725-1735 (1997).
6. "Pack Insert of Methoformin HCl Controlled Release Formulation," Glucophage XR, Bristol-Myers Squibb Co., 2001.
7. Ono I., Matsuda K., Kanno S., J. Chromatogr. B, 692, 397-404 (1997).
8. Maekawa H., Takagishi Y., Iwamoto K., Doi Y., Ogura T., Ito M., Kitamura K., Fujimoto H., Jpn. J. Antibiot., 30, 631-640 (1977).
9. Takagishi Y., Antibiotics Chemotherapy, 2, 1319-1324 (1986).
10. Takagishi Y., J. Jpn. Pharm. Assoc., 37, 113-123 (1985).
11. Ogura T., Clinical Pharmacy, 4, 41-46 (1988).
12. Lehmann K., Drugs Made in Germany, 11, 34-41 (1968).
13. Kokubo H., Obara S., Minemura K., Tanaka T., Chem. Pharm. Bull., 45, 1350-1353 (1997).
14. Kawamori R., Watanabe K., Morishima T., Jpn. J. Clin. Med., 55 (Suppl.), 124-132 (1997).
15. Field J. B., Ann. Rev., 24, 309-314 (1973).
16. Jaspan J., Polonsky K., J. Clin. Invest., 69, 516-525 (1982).
17. Cobelli C., Pacini G., Diabetes, 37, 223-231 (1988).
18. Watanabe R. M., Volund A., Roy S., Bergman R. N., J. Clin. Endocrinol. Metab., 69, 790-797 (1989).